Eraxis Description

Vials containing 100 mg anidulafungin powder and solvent for solution for infusion.
The reconstituted solution contains 3.33 mg/mL anidulafungin and the diluted solution contains 0.77 mg/mL anidulafungin.
Anidulafungin (Eraxis) is a semi-synthetic echinocandin, a lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin selectively inhibits 1,3-β-D-glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall. It has shown fungicidal activity against Candida species and activity against regions of active cell growth of the hyphae of Aspergillus fumigatus.
Anidulafungin (Eraxis) is 1-[(4R,5R)-4,5-Dihydroxy-N²-[[4"-(pentyloxy)[1,1':4',1"-terphenyl]-4yl]carbonyl]-Lornithine]echinocandin B. Anidulafungin is a white to off-white powder that is practically insoluble in water and slightly soluble in ethanol. In addition to the active ingredient, anidulafungin (Eraxis) for injection contains the following inactive ingredients: fructose (50 mg), mannitol (250 mg), polysorbate 80 (125 mg), tartaric acid (5.6 mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment.
The empirical formula of anidulafungin is C₅₈H₇₃N₇O₁₇ and the formula weight is 1140.3.
Excipients/Inactive Ingredients: Fructose, Mannitol (E421), Polysorbate 80 (E433), Tartaric acid (E334), Sodium hydroxide (for pH-adjustment), Hydrochloric acid (for pH-adjustment).